Dr. Fred Hirsch, MD, PhD, has worked with clinical/ translational research in lung cancer for more than 25 years. His current interest is in biomarker developments for early detection, chemoprevention and treatment of lung cancer. He is also studying markers related to molecular targeted therapies in order to understand the mechanisms of action and resistance of these new therapies, and to be able to select the patients who will benefit from such treatment.
The biomarker studies relate to the development of molecular targeted therapies for chemoprevention and treatment of lung cancer including studies on lung cancer cell lines and tumor tissue from clinical cohots. Within the last years focus has been on identifying biomarkers, which can be used to select lung cancer patients to EGFR tyrosine kinase inhibitors and other EGFR inhibitors. Dr. Hirsch’s laboratory is currently studying biomarkers in multiple clinical trials performed in the US and Europe both in lung and head and neck cancer.
Fred Hirsch CV
Article in FirstScience.com: "CU Cancer Center investigator earns prestigious SPECS grant to target squamous cell lung cancer"
Articles in Daily Rx
Articles in Colorado Cancer Blogs
Articles in 1-800-Oncologist.com
Articles in Science Daily
Ecancer.tv Interview: "The role of genetic mutations in lung cancer"